

# Imipenem / Cilastatin / Relebactam Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.4	28.09.2024	9371581-00009	Date of first issue: 27.08.2021

### **SECTION 1:** Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier						
Trade name	:	Imipenem / Cilastatin / Relebactam Formulation				
1.2 Relevant identified uses of the substance or mixture and uses advised against						
Use of the Sub- stance/Mixture	:	Pharmaceutical				
Recommended restrictions on use	:	Not applicable				
1.3 Details of the supplier of the	e saf	ety data sheet				
Company	:	MSD 120 Moorgate EC2M 6UR London, United Kingdom				
Telephone	:	+44 (0) 2081548000				
E-mail address of person responsible for the SDS	:	EHSDATASTEWARD@msd.com				

### 1.4 Emergency telephone number

1-908-423-6000

### **SECTION 2: Hazards identification**

#### 2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK
SI 2019/720, and UK SI 2020/1567)

Eye irritation, Category 2 Respiratory sensitisation, Category 1	H319: Causes serious eye irritation. H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled.
Reproductive toxicity, Category 2 Specific target organ toxicity - repeated exposure, Category 2 Short-term (acute) aquatic hazard, Cate- gory 1	H361d: Suspected of damaging the unborn child. H373: May cause damage to organs through pro- longed or repeated exposure. H400: Very toxic to aquatic life.
Long-term (chronic) aquatic hazard, Cat- egory 1	H410: Very toxic to aquatic life with long lasting effects.

# According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758

### Imipenem / Cilastatin / Relebactam Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.4	28.09.2024	9371581-00009	Date of first issue: 27.08.2021

#### 2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

Hazard pictograms :		
Signal word :	Danger	•
Hazard statements :	H319 H334 H361d H373 H410	Causes serious eye irritation. May cause allergy or asthma symptoms or breath- ing difficulties if inhaled. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure. Very toxic to aquatic life with long lasting effects.
Precautionary statements :	<b>Preventior</b> P260 P273 P280	The protection/ face protection.
	<b>Response</b> : P304 + P34 P342 + P37 P391	40 IF INHALED: Remove person to fresh air and keep comfortable for breathing.

Hazardous components which must be listed on the label: Imipenem Relebactam

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

### **SECTION 3: Composition/information on ingredients**

### 3.2 Mixtures

### Components

Chemical name	CAS-No.	Classification	Concentration
---------------	---------	----------------	---------------

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# Imipenem / Cilastatin / Relebactam Formulation

rsion	Revision Date: 28.09.2024	SDS Number: 9371581-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2027	-
		EC-No. Index-No. Registration	number	(% w/w)
Cilast	atin	81129-83-1 279-694-4	Eye Irrit. 2; H319	>= 30 - < 50
Imipe	nem	74431-23-5	Resp. Sens. 1A; H334 Repr. 2; H361d Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 100 M-Factor (Chronic aquatic toxicity): 10	>= 30 - < 50
Releb	pactam	1174020-13	-3 STOT RE 2; H373 (Kidney)	>= 10 - < 20

For explanation of abbreviations see section 16.

### **SECTION 4: First aid measures**

### 4.1 Description of first aid measures

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled	:	If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn.



# Imipenem / Cilastatin / Relebactam Formulation

Version 4.4	Revision Date: 28.09.2024	SDS Number: 9371581-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021		
		Get medical atte	ntion.		
If swallowed :		Get medical atte	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.		
4.2 Most in	nportant symptoms a	nd effects, both acut	e and delayed		
Risks :		May cause allerg ties if inhaled. Suspected of dat	Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated		
		other respiratory tive airways dysf	sure may aggravate preexisting asthma and disorders (e.g. emphysema, bronchitis, reac- unction syndrome). t can cause mechanical irritation or drying of		

### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment

: Treat symptomatically and supportively.

### **SECTION 5: Firefighting measures**

5.1 Extinguishing media						
Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical				
Unsuitable extinguishing media	:	None known.				
5.2 Special hazards arising from	the	e substance or mixture				
Specific hazards during fire- fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.				
Hazardous combustion prod- ucts	:	Carbon oxides Metal oxides				
5.3 Advice for firefighters						
Special protective equipment for firefighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.				

UK REACH Regulations SI 2019/758



### Imipenem / Cilastatin / Relebactam Formulation

Version	Revision Date: 28.09.2024	SDS Number:	Date of last issue: 06.04.2024
4.4		9371581-00009	Date of first issue: 27.08.2021
Specif ods	ic extinguishing meth-	cumstances and Use water spray	g measures that are appropriate to local cir- the surrounding environment. to cool unopened containers. aged containers from fire area if it is safe to do

### **SECTION 6: Accidental release measures**

#### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
6.2 Environmental precautions Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.
		If spillage enters rivers or watercourses, inform the Environ-

### 6.3 Methods and material for containment and cleaning up

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

### **SECTION 7: Handling and storage**

### 7.1 Precautions for safe handling

Technical measures

Static electricity may accumulate and ignite suspended dust causing an explosion.

ment Agency (emergency telephone number 0800 807060).

:

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# Imipenem / Cilastatin / Relebactam Formulation

Version 4.4	Revision Date: 28.09.2024	SDS Number: 9371581-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
Advic	/Total ventilation e on safe handling	<ul> <li>and bonding.</li> <li>Use only with</li> <li>Do not breath</li> <li>Do not swalled</li> <li>Do not get in</li> <li>Avoid prolon</li> <li>Wash skin the</li> <li>Handle in ac</li> <li>practice, bas</li> <li>sessment</li> <li>Keep contair</li> <li>Already senses</li> <li>to asthma, al</li> <li>should consult of the sense</li> <li>Keep contair</li> <li>Keep away fi</li> <li>Take care to</li> <li>environment.</li> <li>If exposure to</li> <li>flushing systemetical syst</li></ul>	ow. eyes. ged or repeated contact with skin. horoughly after handling. cordance with good industrial hygiene and safety ed on the results of the workplace exposure as- ner tightly closed. sitised individuals, and those susceptible llergies, chronic or recurrent respiratory disease, ult their physician regarding working with respira- or sensitisers. st generation and accumulation. her closed when not in use. rom heat and sources of ignition. tionary measures against static discharges. prevent spills, waste and minimize release to the
		nated clothin The effective engineering appropriate o industrial hyd	g before re-use. e operation of a facility should include review of controls, proper personal protective equipment, degowning and decontamination procedures, giene monitoring, medical surveillance and the istrative controls.
7.2 Condi	tions for safe storage,	including any in	compatibilities
	irements for storage and containers		erly labelled containers. Store locked up. Keep d. Store in accordance with the particular national
Advic	e on common storage	: Do not store Strong oxidiz	with the following product types: zing agents
7.3 Specif	ic end use(s)		
-	fic use(s)	: No data avai	lable

### **SECTION 8: Exposure controls/personal protection**

### 8.1 Control parameters

### Occupational Exposure Limits

dust of any kind

10 mg/m3 Value type (Form of exposure): TWA (Inhalable)

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



### Imipenem / Cilastatin / Relebactam Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.4	28.09.2024	9371581-00009	Date of first issue: 27.08.2021

Basis: GB EH40

4 mg/m3 Value type (Form of exposure): TWA (Respirable fraction) Basis: GB EH40

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Cilastatin	81129-83-1	TWA	5 mg/m3 (OEB 1)	Internal
Imipenem	74431-23-5	TWA	3000 ug/m3 (OEB 1)	Internal
	Further information: RSEN, DSEN			
		Wipe limit	100 µg/100 cm2	Internal
Relebactam	1174020-	TWA	0.3 mg/m3 (OEB 2)	Internal
	13-3			

### 8.2 Exposure controls

#### Engineering measures

Use feasible engineering controls to minimize exposure to compound. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

#### Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection		
Material	:	Chemical-resistant gloves
Skin and body protection Respiratory protection	:	Work uniform or laboratory coat. If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to BS EN 143
Filter type	:	Particulates type (P)

### **SECTION 9: Physical and chemical properties**

### 9.1 Information on basic physical and chemical properties

Appearance Colour Odour Odour Threshold	<ul> <li>powder</li> <li>White to light yellow</li> <li>No data available</li> <li>No data available</li> </ul>
рН	: No data available
Melting point/freezing point	: No data available



Versi 4.4	ion	Revision Date: 28.09.2024		S Number: 71581-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
	Initial b	oiling point and boiling	:	No data available	e
	range Flash p	point	:	Not applicable	
	Evapor	ation rate	:	Not applicable	
	Flamm	ability (solid, gas)	:	May form explos dling or other me	ive dust-air mixture during processing, han- eans.
		explosion limit / Upper ability limit	:	No data available	e
		explosion limit / Lower ability limit	:	No data available	e
,	Vapou	rpressure	:	Not applicable	
	Relativ	e vapour density	:	Not applicable	
	Relativ	e density	:	No data available	9
	Density	/	:	No data available	9
	Partitio octano	ter solubility n coefficient: n- l/water	:	soluble Not applicable	
	Auto-ig	nition temperature	:	No data available	9
	Decom	position temperature	:	No data available	9
	Viscosi Visc	ity cosity, dynamic	:	No data available	9
	Viso	cosity, kinematic	:	Not applicable	
	Explos	ive properties	:	Not explosive	
	Oxidizi	ng properties	:	The substance o	r mixture is not classified as oxidizing.
		nformation			
		ability (liquids)	:	Not applicable	
		ılar weight	:	No data available	
	Particle	e size	:	No data available	e

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758

## Imipenem / Cilastatin / Relebactam Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.4	28.09.2024	9371581-00009	Date of first issue: 27.08.2021

### **SECTION 10: Stability and reactivity**

### 10.1 Reactivity

Not classified as a reactivity hazard.

### **10.2 Chemical stability**

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions	<ul> <li>May form explosive dust-air mixture during processing, han- dling or other means.</li> <li>Can react with strong oxidizing agents.</li> </ul>
10.1 Conditions to sucid	

### 10.4 Conditions to avoid

Conditions to avoid	: Heat, flames and sparks.
	Avoid dust formation.

### **10.5 Incompatible materials**

Materials to avoid	: Oxidizing agents
--------------------	--------------------

### **10.6 Hazardous decomposition products**

No hazardous decomposition products are known.

### **SECTION 11: Toxicological information**

### 11.1 Information on toxicological effects

-		
Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact

### Acute toxicity

Not classified based on available information.

### Components:

### Cilastatin:

Acute oral toxicity	:	LD50 (Rat): 8,000 mg/kg
		LD50 (Mouse): 8,000 mg/kg
Imipenem:		
Acute oral toxicity	:	LD50 (Mouse): 10,000 mg/kg
Acute toxicity (other routes of administration)	:	LD50 (Rat): > 2,000 mg/kg Application Route: Intravenous
		LD50 (Mouse): 1,500 mg/kg Application Route: Intravenous



# Imipenem / Cilastatin / Relebactam Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.4	28.09.2024	9371581-00009	Date of first issue: 27.08.2021

### Skin corrosion/irritation

Not classified based on available information.

#### Components:

#### Cilastatin:

Species	:	Rabbit
Result	:	No skin irritation

### Relebactam:

Method	:	EpiDerm
Result	:	No skin irritation

### Serious eye damage/eye irritation

Causes serious eye irritation.

### **Components:**

#### Cilastatin:

••••••••••		
Species	:	Rabbit
Result	:	Moderate eye irritation

#### Relebactam:

Method	:	Bovine cornea (BCOP)
Result	:	No eye irritation

#### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### Respiratory sensitisation

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

### **Components:**

Cilastatin:		
Exposure routes	:	Skin contact
Remarks	:	No data available
Exposure routes	:	Inhalation
Remarks	:	No data available
Imipenem:		
Remarks	:	May cause sensitisation of susceptible persons by inhalation of aerosol or dust.
Exposure routes	:	Skin contact



			09 Date of first issue: 27.08.2021
Rema	rks	: Not classi	fied due to lack of data.
Releb	actam:		
Test T	vpe	: Local lym	ph node assay (LLNA)
	sure routes	: Dermal	
Resul	t	: Not a skin	sensitizer.
	cell mutagenicity assified based on ava	ailable informatior	).
Comp	oonents:		
Cilast	atin:		
Genot	toxicity in vitro	: Test Type Result: ne	e: Microbial mutagenesis assay (Ames test) egative
Imipe	nem:		
Genot	toxicity in vitro	: Test Type	: In vitro mammalian cell gene mutation test
	•		em: Chinese hamster lung cells
		Result: ne	egative
		Test Type	: reverse mutation assay
		Result: ne	
		Test Type	: unscheduled DNA synthesis assay
		Result: ne	
		Toot Type	: Chromosomal aberration
		Result: ne	
			-
			: sister chromatid exchange assay
		Result: ne	galive
Genot	toxicity in vivo		: In vivo micronucleus test
		Species: I	
			n Route: Intravenous
		Result: ne	gative
Releb	actam:		
Genot	toxicity in vitro	: Test Type	: Bacterial reverse mutation assay (AMES)
	-	Result: ne	
		Test Type	: Chromosome aberration test in vitro
		Result: ne	
Genot	toxicity in vivo	: Test Type	: Mutagenicity (in vivo mammalian bone-marrow
20.00	····, ·····		ic test, chromosomal analysis)
		Species: I	Rat
			n Route: Intraperitoneal injection



Ver 4.4	sion	Revision Date: 28.09.2024		9S Number: 71581-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
				Result: negative	
	Germ o sessme	ell mutagenicity- As- ent	:	Weight of evidenc cell mutagen.	e does not support classification as a germ
		<b>ogenicity</b> ssified based on availa	ble	information.	
	Suspec	<b>fuctive toxicity</b> sted of damaging the u	nbo	rn child.	
	Compo				
	Cilasta Effects	tin: on fertility	:	Application Route Fertility: LOAEL: Symptoms: No ac	1,000 Iverse effects s on fertility and early embryonic develop-
	Imipen	em:			
	-	on fertility	:	Species: Rat, mal Application Route Fertility: LOAEL: 8 Symptoms: No ac	: Intravenous 30 mg/kg body weight Iverse effects, Reduced foetal weight 5 on fertility and early embryonic develop-
				Species: Rat, mal Application Route Fertility: LOAEL: 3 Symptoms: No ac	: Subcutaneous 320 mg/kg body weight Iverse effects, Reduced foetal weight 5 on fertility and early embryonic develop-
	Effects ment	on foetal develop-	:	Result: Embryoto	
				Test Type: Develo Species: Rabbit Application Route Developmental To Result: No teratoo	: Intravenous oxicity: NOAEL: 60 mg/kg body weight

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



ersion .4	Revision Date: 28.09.2024	SDS Number: 9371581-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
		Development	evelopment oute: Intravenous al Toxicity: NOAEL: 60 mg/kg body weight ratogenic effects
Repro sessr	oductive toxicity - As- nent	: Some eviden animal exper	ce of adverse effects on development, based on iments.
Relet	pactam:		
	ts on fertility	Species: Rat Application R	re-/postnatal development oute: Subcutaneous .EL: 450 mg/kg body weight
Effect ment	ts on foetal develop-	Species: Rat Application R Embryo-foeta	mbryo-foetal development oute: Intraperitoneal injection al toxicity: NOAEL: 450 mg/kg body weight fects on foetal development
		Species: Mou Application R Embryo-foeta	mbryo-foetal development use oute: Intraperitoneal injection al toxicity: NOAEL: 450 mg/kg body weight fects on foetal development
		Development	oute: Intravenous al Toxicity: NOAEL: >= 450 mg/kg body weight fects on fertility and early embryonic develop-
		Development	
	<b>- single exposure</b> lassified based on avai	lable information.	
	<b>- repeated exposure</b>		d or repeated exposure.
-	ponents:		
	pactam:		

Reference		
Target Organs Assessment	:	Kidney May cause damage to organs through prolonged or repeated

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



ersion 4	Revision Date: 28.09.2024	SDS Number: 9371581-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
		exposure.	
Repe	ated dose toxicity		
Com	ponents:		
Cilas	tatin:		
	EL cation Route sure time	: Rat : >= 500 mg/kg : Intravenous : 90 Days : No significant a	dverse effects were reported
Speci		: Monkey	
NOAE Applic	EL cation Route sure time	: >= 500 mg/kg : Intravenous : 5 Weeks	dverse effects were reported
Imipe	enem:		
Expos	ΞL	: Monkey : 60 mg/kg : 150 mg/kg : Intravenous : 6 Months : Kidney	
	EL cation Route sure time	: Monkey : 120 mg/kg : Subcutaneous : 6 Months : No significant a	dverse effects were reported
	EL cation Route sure time	: Rat : 180 mg/kg : Intravenous : 6 Months : No significant a	dverse effects were reported
		: Rabbit : 150 mg/kg : Intravenous : Kidney	
Relet	pactam:		
		: Rat, female : 150 mg/kg : Intravenous : 30 d	

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# Imipenem / Cilastatin / Relebactam Formulation

rsion	Revision Date: 28.09.2024	SDS Number: 9371581-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
Speci	es	: Rat, male	
NOAE		: 450 mg/kg	
	ation Route	: Intravenous	
Expos	sure time	: 30 d	
Speci		: Monkey	
NOAE		: 25 mg/kg	
	cation Route	: Intravenous : 30 d	
	sure time t Organs	: Kidney	
Speci	95	: Monkey	
NOAE		: 37.5 mg/kg	
-	ation Route	: Intravenous	
	sure time	: 30 d	
Speci	es	: Monkey	
NOAE		: 50 mg/kg	
LOAE		: 150 mg/kg	
	cation Route	: Intravenous : 3 Months	
	sure time t Organs	: Kidney	
Aspir	ation toxicity		
-	assified based on ava	ailable information.	
Expe	rience with human e	xposure	
<u>Comp</u>	oonents:		
Imipe	nem:		
Inhala	ation	Dizziness, D Remarks: M	Nausea, Vomiting, Diarrhoea, Fever, hypotensio rowsiness, Convulsions, pruritis, Rash ay cause sensitisation of susceptible persons b aerosol or dust.
Releb	oactam:		
Skin o	contact		Pain, Discomfort, Diarrhoea, Abdominal pain, ausea, sore throat, Vertigo

### 12.1 Toxicitv

۷.	TOXICITY		
	Components:		
	Cilastatin:		
	Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): > 111 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
	Toxicity to daphnia and other	:	EC50 (Daphnia magna (Water flea)): > 99 mg/l
			15/04



Version 4.4	Revision Date: 28.09.2024		9S Number: 71581-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
aqua	atic invertebrates		Exposure time: 48 Method: OECD Te	
Toxi plan	city to algae/aquatic ts	:	EC50 (Anabaena Exposure time: 72 Method: OECD Te	
			EC50 (Pseudokiro mg/l Exposure time: 72 Method: OECD Te	
			NOEC (Anabaena Exposure time: 72 Method: OECD Te	
			NOEC (Pseudokir mg/l Exposure time: 72 Method: OECD Te	
Toxi	city to microorganisms	:	EC50 : > 1,000 m Exposure time: 3 Test Type: Respir Method: OECD Te	h ation inhibition
Toxi icity)	city to fish (Chronic tox-	:	Exposure time: 32	ales promelas (fathead minnow)
aqua	city to daphnia and other atic invertebrates (Chron- kicity)	:	Exposure time: 21	magna (Water flea)
Imip	enem:			
Toxi	city to daphnia and other atic invertebrates	:	EC50 (Daphnia m Exposure time: 48 Method: OECD Te	
Toxi plan	city to algae/aquatic ts	:	EC50 (Anabaena Exposure time: 72 Method: OECD Te	
			NOEC (Anabaena Exposure time: 72 Method: OECD Te	
			EC50 (Pseudokiro mg/l	chneriella subcapitata (green algae)): > 74

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Versio 4.4	on	Revision Date: 28.09.2024		9S Number: 71581-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
				Exposure time: 72 Method: OECD Te	
				NOEC (Pseudokir mg/l Exposure time: 72 Method: OECD Te	
	И-Facto city)	or (Acute aquatic tox-	:	100	
Т	Foxicity	to microorganisms	:	EC50 : > 1,000 m Exposure time: 3 Test Type: Respir Method: OECD Te	h ation inhibition
	Γoxicity city)	to fish (Chronic tox-	:	NOEC: 9.4 mg/l Exposure time: 32 Species: Pimepha Method: OECD Te	lles promelas (fathead minnow)
а		to daphnia and other invertebrates (Chron- ty)	:	NOEC: 11 mg/l Exposure time: 21 Species: Daphnia Method: OECD Te	magna (Water flea)
	И-Facto oxicity)	or (Chronic aquatic	:	10	
F	Releba	ctam:			
		to daphnia and other invertebrates	:	EC50 (Daphnia m Exposure time: 48 Method: OECD Te	
				EC50 (Americamy Exposure time: 96	
	Foxicity plants	to algae/aquatic	:	EC50 (Pseudokiro Exposure time: 72 Method: OECD Te	
				NOEC (Pseudokir mg/l Exposure time: 72 Method: OECD Te	
				EC50 (Anabaena Exposure time: 72 Method: OECD Te	
				NOEC (Anabaena Exposure time: 72	n flos-aquae (cyanobacterium)): 11 mg/l ? h



Versio 4.4	on	Revision Date: 28.09.2024		9S Number: 71581-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
				Method: OECD To	est Guideline 201
ſ	Foxicity	to microorganisms	:	EC50 : > 1,000 m Exposure time: 3 Test Type: Respir Method: OECD Te	h ration inhibition
				NOEC : 96.3 mg/l Exposure time: 3 Test Type: Respir Method: OECD Te	h ation inhibition
	Foxicity city)	to fish (Chronic tox-	:	NOEC: 9.2 mg/l Exposure time: 32 Species: Pimepha Method: OECD To	ales promelas (fathead minnow)
a		to daphnia and other invertebrates (Chron- ty)	:	NOEC: 2.7 mg/l Exposure time: 21 Species: Daphnia Method: OECD Te	magna (Water flea)
12.2 I	Persist	ence and degradabil	ity		
<u>(</u>	Compo	nents:			
-	Cilastat				
E	Biodegr	adability	:	Result: Not readily Biodegradation: 2 Exposure time: 28 Method: OECD Te	27 %
I	mipene	em:			
E	Biodegr	adability	:	Result: Not readily Biodegradation: 2 Exposure time: 28 Method: OECD T	29 %
	Releba	ctam.			
-		adability	:	Result: Not readily Biodegradation: Exposure time: 28 Method: OECD To	11.3 % 3 d
12.3 I	Bioacc	umulative potential			
<u>(</u>	Compo	nents:			
C	Cilasta	tin:			
F	Partitior	n coefficient: n-	:	log Pow: -3.53	



# Imipenem / Cilastatin / Relebactam Formulation

Version 4.4	Revision Date: 28.09.2024		DS Number: 371581-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
octa	anol/water			
Imij	penem:			
	tition coefficient: n- anol/water	:	log Pow: < -1	
Rel	ebactam:			
	tition coefficient: n- anol/water	:	log Pow: < -2	
12.4 Mo	bility in soil			
Cor	nponents:			
Cila	statin:			
	ribution among environ- ntal compartments	:	log Koc: 2.3	
Rele	ebactam:			
	ribution among environ- ntal compartments	:	log Koc: 2.3	
12.5 Res	sults of PBT and vPvB a	sse	ssment	
Pro	duct:			
Ass	essment	:	to be either persi	nixture contains no components considered stent, bioaccumulative and toxic (PBT), or nd very bioaccumulative (vPvB) at levels of
12.6 Oth	er adverse effects			
<u>Pro</u>	duct:			
	ocrine disrupting poten-	:	ered to have end	nixture does not contain components consid- ocrine disrupting properties for environment REACH Article 57(f).

### **SECTION 13: Disposal considerations**

13.1 Waste treatment methods	
Product	<ul> <li>Dispose of in accordance with local regulations.</li> <li>According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.</li> <li>Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.</li> <li>Do not dispose of waste into sewer.</li> </ul>
Contaminated packaging	<ul> <li>Empty containers should be taken to an approved waste han- dling site for recycling or disposal.</li> <li>If not otherwise specified: Dispose of as unused product.</li> </ul>



Version 4.4	Revision Date: 28.09.2024		OS Number: 71581-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
SECTION	14: Transport infor	mat	lion	
14.1 UN n	umber			
ADN		:	UN 3077	
ADR		:	UN 3077	
RID		:	UN 3077	
IMDG	ì	:	UN 3077	
ΙΑΤΑ		:	UN 3077	
14.2 UN p	roper shipping name			
ADN		:	ENVIRONMENT/ N.O.S. (Imipenem)	ALLY HAZARDOUS SUBSTANCE, SOLID,
ADR		:	ENVIRONMENT/ N.O.S. (Imipenem)	ALLY HAZARDOUS SUBSTANCE, SOLID,
RID		:	ENVIRONMENT/ N.O.S. (Imipenem)	ALLY HAZARDOUS SUBSTANCE, SOLID,
IMDG	i	:	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SC N.O.S. (Imipenem)	
ΙΑΤΑ		:	Environmentally I (Imipenem)	nazardous substance, solid, n.o.s.
14.3 Trans	sport hazard class(es)			
			Class	Subsidiary risks
ADN		:	9	
ADR		:	9	
RID		:	9	
IMDG	ì	:	9	
ΙΑΤΑ		:	9	
14.4 Pack	ing group			
Class Hazaı Label: <b>ADR</b> Packi	ng group ification Code rd Identification Number s ng group ification Code	:	III M7 90 9 1II M7	



# Imipenem / Cilastatin / Relebactam Formulation

Versio 4.4	on	Revision Date: 28.09.2024		0S Number: 71581-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
L	abels	Identification Number restriction code	:	90 9 (-)	
F C F		g group cation Code Identification Number	: :	III M7 90 9	
F	I <b>MDG</b> Packing Labels EmS Co		:	III 9 F-A, S-F	
F 8 F F	aircraft)	g instruction (cargo	:	956 Y956 III Miscellaneous	
F G F F	Packing ger airc Packing	Passenger) g instruction (passen- raft) g instruction (LQ) g group	:	956 Y956 III Miscellaneous	
14.5 E	Enviro	nmental hazards			
	<b>ADN</b> Environ	mentally hazardous	:	yes	
	<b>ADR</b> Environ	mentally hazardous	:	yes	
	<b>RID</b> Environ	mentally hazardous	:	yes	
	I <b>MDG</b> Marine	pollutant	:	yes	
		Passenger) mentally hazardous	:	yes	
	I <b>ATA (C</b> Environ	Cargo) mentally hazardous	:	yes	
14.6 \$	Specia	I precautions for use	r		

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

: Not applicable for product as supplied.

### 14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks



### Imipenem / Cilastatin / Relebactam Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.4	28.09.2024	9371581-00009	Date of first issue: 27.08.2021

### **SECTION 15: Regulatory information**

#### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Relevant EU provisions transposed through retained EU law

UK REACH List of restrict	ions (Annex 17)	:	Not applicable	
UK REACH Candidate list concern (SVHC) for Author	of substances of very high	:	Not applicable	
The Persistent Organic Po	Ilutants Regulations (retained 1 as amended for Great Brit-	:	Not applicable	
,	ances that deplete the ozone	:	Not applicable	
5	nces subject to authorisation	:	Not applicable	
GB Export and import of h Informed Consent (PIC) R	azardous chemicals - Prior egulation	:	Not applicable	
Control of Major Accident	Hazards Regulations 2015 (CC	DMA	NH)	
E1	ENVIRONMENTAL		Quantity 1 100 t	Quantity 2 200 t

### Other regulations:

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to new and expectant mothers at work contained in Regulation 16 to 18) and of the Pregnant Workers Directive 92/85/EEC.

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to protection of young people at work contained in Regulation 19) and of Directive 94/33/EC on the protection of young people at work.

#### The components of this product are reported in the following inventories:

HAZARDS

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

### **SECTION 16: Other information**

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



### Imipenem / Cilastatin / Relebactam Formulation

Version 4.4	Revision Date: 28.09.2024	SDS Number: 9371581-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021	
Full t	ext of H-Statements			
H319		: Causes serio	us eye irritation.	
H334			May cause allergy or asthma symptoms or breathing difficul- ties if inhaled.	
H361	d	: Suspected of	Suspected of damaging the unborn child.	
H373	;	: May cause da exposure.	May cause damage to organs through prolonged or repeated exposure.	
H400		: Very toxic to a	Very toxic to aquatic life.	
H410		: Very toxic to a	Very toxic to aquatic life with long lasting effects.	
Full t	ext of other abbrevia	tions		
Aqua	tic Acute		cute) aquatic hazard	
	tic Chronic		Long-term (chronic) aquatic hazard	
Eye I			Eye irritation	
Repr			Reproductive toxicity	
	. Sens.	1 2	Respiratory sensitisation	
STO			Specific target organ toxicity - repeated exposure	
GB E			UK. EH40 WEL - Workplace Exposure Limits	
GB E	H40 / TWA	: Long-term ex	posure limit (8-hour TWA reference period)	
Wate Road ing of tion ( of the	rways; ADR - Agreem l; AIIC - Australian Inve f Materials; bw - Body EC) No 1272/2008; CM e German Institute for	nent concerning the entory of Industrial C weight; CLP - Class /IR - Carcinogen, M Standardisation; DS	rnational Carriage of Dangerous Goods by Inland International Carriage of Dangerous Goods by hemicals; ASTM - American Society for the Test- ification Labelling Packaging Regulation; Regula- utagen or Reproductive Toxicant; DIN - Standard L - Domestic Substances List (Canada); ECHA - ropean Community number; ECx - Concentration	

d European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals: OECD - Organization for Economic Co-operation and Development: OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative



### Imipenem / Cilastatin / Relebactam Formulation

4.4         28.09.2024         9371581-00009         Date of first issue: 27.08.2021	Version 4.4	Revision Date: 28.09.2024	SDS Number: 9371581-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021	
--	----------------	---------------------------	------------------------------	---	--

### Further information

Sources of key data used to compile the Safety Data Sheet	-	data from raw material SDSs, OECD esults and European Chemicals Agen- eu/
Classification of the mixtu	ire:	Classification procedure:
Eye Irrit. 2	H319	Calculation method
Resp. Sens. 1	H334	Calculation method
Repr. 2	H361d	Calculation method
STOT RE 2	H373	Calculation method
Aquatic Acute 1	H400	Calculation method
Aquatic Chronic 1	H410	Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

### GB / EN